Novo Nordisk India partners with Emcure Pharma to commercialize ‘Poviztra’ in India

New Delhi: Novo Nordisk India and Emcure Pharmaceuticals have announced a strategic partnership to launch Poviztra® (semaglutide injection 2.4 mg) in India. The collaboration aims to strengthen the distribution and marketing of semaglutide for weight management, particularly expanding access through pharmacies and regions beyond Novo Nordisk India’s current reach.

Poviztra® is the second brand of Wegovy®, the semaglutide injection 2.4 mg formulation that Novo Nordisk launched in India in June 2025. Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management and for reducing the risk of major adverse cardiovascular events in individuals who are overweight or living with obesity. Clinical trials have shown that one in three participants on Wegovy® achieved over 20% weight loss.

Under the new agreement, Emcure Pharma will serve as the exclusive distributor, handling the commercialisation and marketing of Poviztra® across India. The partnership represents a key step in Novo Nordisk India’s commitment to broaden access to innovative, evidence-based obesity treatments.

“Obesity is a serious chronic disease affecting millions of people across India and results in significant unmet medical needs,” said Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk. “Recognising the magnitude of this challenge, we launched Wegovy® in India a few months ago. Now, with Emcure Pharma, we aim to extend access to this high-quality, safe, and effective treatment. This partnership brings together Novo Nordisk’s innovation in GLP-1 therapies and Emcure’s strong distribution and marketing network to reach more people living with overweight or obesity.”

Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma, added, “We are thrilled to partner with Novo Nordisk India to bring Poviztra® to India and proud to be the first Indian pharmaceutical company to introduce the world’s most trusted GLP-1-based weight loss molecule. With our deep understanding of India’s diverse market and established presence, we are confident in making this treatment accessible to those who need it most.”

Semaglutide injection 2.4 mg (Wegovy®/Poviztra®) has demonstrated strong clinical efficacy in multiple obesity trials under the STEP and SELECT programmes. The semaglutide molecule, which has been available globally for nearly a decade, accounts for 38 million patient years of exposure and is supported by robust real-world evidence.